Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Honeywell (HON) and Morgan Stanley (MS).

    Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN

    Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.

      J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

      Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

        Swarup Gupta headshot

        Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress

        The Dow experienced a particularly volatile week as earnings results took center stage.

          Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

          Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

            3 Dividend ETFs With High Inflows in April

            Consider these three dividend ETFs to fend off growing market uncertainty.

              Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better

              Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.

                New Construction Data, Q1 Earnings In Focus

                New Construction Data, Q1 Earnings In Focus

                  Mark Vickery headshot

                  Tax Day Not So Taxing (for Corporations, Housing)

                  Strength in Q1 earnings season, at least in these early stages, has helped bolster market indexes. This continues ahead of Tuesday's market open.

                    J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

                    J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

                      J&J (JNJ) Beats on Q1 Earnings & Sales, Ups 2018 Sales View

                      J&J (JNJ) beat estimates for both earnings and sales in the first quarter of 2018. It maintained the previously issued earnings guidance for 2018 while increasing the sales range.

                        Tracey Ryniec headshot

                        5 of the Best Big Cap Earnings Charts

                        These big cap companies almost always beat the estimate on earnings but will that change in 2018?

                          Here's Why Geron Stock Surged More Than 90% in 6 Months

                          Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

                            Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

                            The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                              J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?

                              The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                                Karyopharm's Myeloma Candidate Gets Fast Track Designation

                                The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.

                                  Tirthankar Chakraborty headshot

                                  4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings

                                  The recent tax code overhaul and a strengthening economy could certainly help blue-chip companies make more money this upcoming earnings season.

                                    Indrajit Bandyopadhyay headshot

                                    4 Drug/Biotech Stocks to Buy Ahead of World Health Day

                                    Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.

                                      The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson

                                      The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson

                                        FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus

                                        The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.

                                          Tirthankar Chakraborty headshot

                                          Wall Street Brushes Off Trade War Fears: Top 5 Gainers

                                          The Dow climbed more than 700 points after investors downplayed fears over tariffs announced by both China and the United States.

                                            Allergan's Vraylar Meets Endpoints in Bipolar I Phase III

                                            Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.

                                              AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use

                                              AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.

                                                Shire's Stock Continues to Rise as Takeda Sets Eyes On it

                                                Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton